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ABSTRACT 
Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats 
Natalie R. Bruner 
Kava-kava is a widely available and used herbal medicine that is not regulated in many 
countries, including the United States. There are many questions concerning kava-kava’s 
stimulus properties, potential for therapeutic use, and potential for abuse. Although there is 
evidence that kava may possess some anxiolytic properties, the supplement’s mechanism of 
action and the extent to which it may serve as an alternative to pharmaceutical anxiolytics are 
unknown. To date, there is no research examining whether kava shares discriminative-stimulus 
properties with a standard pharmaceutical anxiolytic such as chlordiazepoxide (CDP). The 
current study compared different doses of kava in two groups of rats trained to discriminate 
either a high or low training dose of CDP (i.p.). In order to assess time-course effects of kava 
(p.o.), two tests were conducted per session at 60 (Test One) and 90 (Test Two) min following 
administration of kava, CDP, or d-amphetamine. Dose-dependent substitution of CDP was found 
in both training groups. d-Amphetamine did not substitute for either group at Test One, but 
marginal substitution was found in both groups at the lower doses of d-amphetamine during Test 
Two. Kava (560 mg/kg) occasioned responding indicative of partial substitution in both groups 
during Test One and only the low-dose group during Test Two. Several procedural variables that 



















I would first like to thank my advisor, Dr. Karen Anderson, for her guidance and support 
throughout the duration of this thesis project. Not only did this thesis present a valuable and 
challenging learning experience for me, but it also offered an excellent opportunity for intellectual 
and personal growth. It was Karen’s frank, encouraging, and caring attitude that created an 
environment conducive to success. I would also like to thank to Dr. Andy Lattal and Dr. Hawley 
Montgomery-Downs for serving on my thesis committee and offering their expert advice and 
support.  
I would like to thank my lab-mates and friends James Diller and Jonathan Slezak for 
countless hours spent discussing this project as well as their kind words of encouragement 
throughout the process. I also very much appreciate those numerous undergraduate research 
















Table of Contents  
Abstract……………………………………………………………………………………………ii  
Acknowledgments………....……………………………………………………………………..iii  
List of Tables…….………..……...……………………………………………………………….v 
List of Figures…...…………….....…………………………………...…..…….………………...vi 
Discriminative-stimulus and time-course effects of kava-kava in rats…………........………....1       
Literature Review…………............……………………………………………………………….2  





Initial training……………………………………………………………………..8  
Discrimination training……………………………....……………………………9  
Generalization testing……………………………......…………………………..10  
Drugs…………................................…………………………………………….10  
Data analyses............…………………………………………………………….11  
Results……………………………………………………………………………………………13  
Initial training……………..............…....……...………………………………………..13 
Generalization of CDP…………………………………………………………………..14 
Generalization of saline vehicle..………………………………………………………..25  
Generalization of d-amphetamine.….……..………........……………………………….25  












List of Tables 
Table 1: Percent responding following CDP administration during Test One……...........…...…....15 
Table 2: Percent responding following CDP administration during Test Two …….…...........……16  
Table 3: Percent responding following d-amphetamine administration...........……....……..……...17  
Table 4: Percent responding following kava administration …………...............................……….18  
Table 5: Responses per minute following CDP administration during Test One ……….………...19  
Table 6: Responses per minute following CDP administration during Test Two ……………...…20 
Table 7: Responses per minute following d-amphetamine during Test One ……........…………...21 
Table 8: Responses per minute following kava administration during Test One ……….………...22  
 
vi 
List of Figures  
Figure 1: Mean percent responding as a function of test dose……...…..............................……....23  



















Discriminative-stimulus and time-course effects of kava-kava in rats 
 For hundreds of years, the people of the South Pacific have consumed the beverage kava-
kava (kava) for ceremonial, medicinal and social purposes (Singh, 1992). The importance of 
kava in the life of the South Pacific islanders is analogous to the use of alcohol in other cultures. 
Cultivated from the tropical shrub Piper methysticum (meaning “intoxicating pepper”), the 
traditional preparation consists of grinding down the thick kava root into an intoxicating murky 
beverage. Consuming the beverage induces a relaxed state and can help to improve social 
interaction (Stolerman, 1993). Kava has also been traditionally used as a natural anti-anxiety or 
sedative medicine.  
 It was not until the 1990’s that kava gained significant attention as an herbal alternative 
to pharmaceutical drugs for treatment of stress, anxiety, and pain. By 1994, kava had become 
one of the top eight herbal remedies in the $18 million herbal remedy industry (O’Sullivan & 
Lum, 2004). In 2002, several European countries banned the sales of the herb due to cases of 
severe hepatic toxicity in users of kava. Because it is classified as an herbal supplement, the 
Food and Drug Administration (FDA) of the United States does not regulate the quality of nor 
approve preparations of kava prior to its marketing. However, following the European ban on 
kava in 2002, the FDA did issue a consumer advisory pertaining to the potential harmful effects 
of the herb. Subsequently, several herbal remedy retailers voluntarily withdrew kava-containing 
items from their stores (O’Sullivan & Lum, 2004). The potential toxic effects as well as the 






Kava-kava’s active pharmacological agents consist of 18 compounds called kavalactones. 
Six of these kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, 
and desmethysticin) account for about 95% of the kava extract (Ganzera & Khan, 1999).  Smith 
et al. (2001) found that of the six major kavalactones tested individually in a chick social 
separation-stress paradigm, only dihydrokavain resulted in behavioral effects similar to those 
following administration of the benzodiazepine chlordiazepoxide (CDP). Feltenstein et al. (2003) 
reported that kava fractions containing the highest doses of dihydrokavain moderately 
suppressed both distress vocalizations and stress-induced analgesia. These studies suggest that 
some properties of kava may be similar to those of established anxiolytic drugs. More research is 
needed to determine whether these shared stimulus properties of kava extract are mediated by the 
total kavalactone content or from particular kavalactones.   
Kavalactones appear to interact with GABAA receptors (Jussofie, Schmiz, & Heimke, 
1994; Singh, 2005). These are the same receptor sites that anti-anxiety drugs such as 
chlordiazepoxide and diazepam act upon. If kava affects the same receptors as these 
benzodiazepines, it may be expected to have shared stimulus properties and anxiolytic effects.  
Research investigating the use of kava in human participants supports kava as an 
effective treatment for anxiety. Geier & Konstantinowicz (2004) used the Hamilton Anxiety 
Scale as a primary dependent variable to assess self-rated subjective level of anxiety before and 
after kava treatment. It was found that patients had a therapeutically relevant reduction in anxiety 
in the kava-extract group compared to the placebo-control group. Another study with human 
participants supports the finding that kava is beneficial for treating anxiety symptoms in anxiety 
patients terminating treatment with benzodiazepines (Malsch & Kieser, 2001). This suggests that 
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kava may be an effective substitute for pharmaceutical anxiolytics such as benzodiazepines. 
Ernst (2006) conducted a systematic review of controlled clinical trials summarizing the 
anxiolytic efficacy of herbal medicines. It was reported that kava is the only herbal medicine that 
has been shown to have anxiolytic effects in humans.  
 The data concerning kava using animal models of anxiety is limited. Garrett, Basmadjian, 
Khan, Schaneberg, and Seale (2003) found that kava extract significantly increased changes in 
behavior, in a manner similar to that of drugs established as anxiolytics in humans, in two animal 
models of anxiety. In the mirrored-chamber avoidance paradigm, a mouse entering the mirrored 
chamber is surrounded by its own reflection on six sides. In the elevated-plus maze paradigm, 
Plexiglas surrounds the arms of one runway of the maze, and the arms of the other runway are 
open. Animal subjects in these assays typically spend less time in the mirrored chamber or open 
arms of the elevated-plus maze relative to time spent in the enclosed runway leading into the 
mirrored chamber or closed arms of the maze. However, following administration of a 
benzodiazepine, time spent in the mirrored chamber or open arms of the maze is increased. 
Administration of kava in these animal models of anxiety results in behavioral effects similar to 
those following administration of benzodiazepines. Kava extract injected intraperitoneally (i.p.) 
reduced both latency to enter and increased time spent in both the mirrored chamber of the 
mirrored-chamber avoidance assay and the open arms of the elevated-plus maze assay, compared 
to administration of vehicle. Rex, Morgenstern, & Fink (2002) used an elevated-plus maze to 
determine orally administered (p.o.) kava-induced effects on time spent in the open arms of the 
maze compared to the standard anxiolytic diazepam. They reported that kava extract (120-240 
mg/kg) and diazepam (15 mg/kg) significantly affected the time spent in the open arms and 
open-arm visits. Smith et al. (2001) used the chick social separation-stress paradigm to assess the 
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behavioral effects of i.p. administered kava extract and isolated kavalactones. They found that 
kava extract (30 mg/kg) and the kavalactone dihydrokavain (30 mg/kg) resulted in responses 
comparable to that following administration of the “gold standard” anxiolytic CDP (5 mg/kg, 
i.p.).  
 Positive results in three experimental paradigms across three species of animals suggest 
that kava has effects on behavior similar to those produced by drugs classified as anxiolytics in 
clinical settings with humans. To date, there are no studies examining the discriminative-
stimulus properties of kava in animals. The discriminative-stimulus properties of drugs may be 
evaluated in a drug-discrimination procedure. The proposed study will determine if kava shares 
discriminative-stimulus properties similar to those of CDP using rats as subjects.  
The subjective effects of drugs may be trained to serve as discriminative stimuli using a 
drug-discrimination procedure. In such a procedure, a discrimination is trained between a 
specific dose of a drug and its vehicle (e.g., saline).  In drug-discrimination training, one activity 
(i.e., pressing a lever) is reinforced after drug administration and another activity (i.e., pressing a 
second lever) is reinforced in the absence of the drug (i.e., after vehicle administration). If 
differential responding is observed in drug-appropriate lever-pressing vs. non-drug or vehicle-
appropriate lever-pressing, then it may be concluded that the drug’s effects are acting as a 
discriminative-stimulus (Branch, 1991). A common dosing schedule for drug (D) and vehicle (V) 
in a two-week period (Monday-Friday) is VDVDD DVDVV. For drug days, one set of 
contingencies is in effect (i.e., reinforcement available on the drug-appropriate lever). On vehicle 
(non-drug) days, a second set of contingencies is in effect (i.e., reinforcement available on the 
vehicle-appropriate lever).  
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The drug-discrimination procedure may be used to ascertain whether another test drug 
shares discriminative-stimulus properties with the training drug. A discrimination between the 
training drug and vehicle is generally considered established when there is at least 80% correct 
responding on the drug-appropriate lever following administration of the training drug. 
Following drug training, another dose of the training drug or other drugs may be administered 
prior to a test session. Drugs within the same pharmacological class and novel compounds are 
often substituted to assess the extent to which the test drug may substitute for the training drug. 
To establish that responding on the drug-appropriate lever indicates shared discriminative-
stimulus properties with the training drug and is not an artifact of general administration of a 
drug, a negative control (usually a drug from another pharmacological class) is often included in 
testing.  
Stimulus generalization may be assessed using either quantal or graded measures. 
Quantal indices characterize discriminative responses as all-or-none. They are measured using 
nominal scales and are usually averaged across subjects (Stolerman, 1993). Graded indices may 
allow for partial substitution of the test drugs and may be measured within and across subjects. 
In a graded index, the proportion of responses corresponding to one of the options (i.e., 
percentage of total responses on drug-appropriate lever) may be used for data analysis. To ensure 
that reinforcement is not serving a discriminative function, data analysis of test sessions are 
based on responses made prior to reinforcer delivery, or discrimination tests are conducted in 
extinction. Full generalization to the training drug is usually defined as at least 80% responding 
on the drug-appropriate lever, 21-79% as partial substitution, and less than or equal to 20% of 
total responses is characterized as no substitution. A dose-response function with the test drug 
may be compared to the dose-response function generated during the initial drug training in the 
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form of a generalization gradient. Generalization gradients plot the extent to which the test drug 
produces a dose-effect curve similar to that of the training drug.  
There are several variables that may influence generalization gradients. The dose used for 
the training drug to establish and maintain a discrimination influences sensitivity to the drug.  A 
relatively low training dose will generally result in greater sensitivity to test stimuli, and dose-
response curves will subsequently be shifted to the left. Discriminations with relatively high 
doses are generally easier to establish (i.e., requires fewer training sessions), but may result in 
less sensitivity to discriminative-stimulus properties of test stimuli than that based on lower 
training doses. The schedule of reinforcement used in training is another important factor to 
consider. A schedule such as a relatively small fixed-ratio (FR) is often utilized for its capacity to 
engender strong stimulus control (Stolerman, 1993). Using this schedule, responses are usually 
emitted on a lever as a single unit, resulting in data that are more quantal in nature. A schedule 
such as a variable-interval (VI), which may result in responses distributed between the two 
choices, may result in data that are more graded in nature. However, VI schedules are 
characterized by a poorer capacity for engendering stimulus control. Tandem VI-FR schedules 
combine the advantages of these two schedules: strong stimulus control as well as fostering 
responding that may result in data that are graded in nature. Pharmacokinetics of the drug with 
respect to time-course effects is another important variable affecting the generalization gradient. 
The onset and duration of the drug’s action will influence the point in time in which a test drug 
may share discriminative-stimulus properties with the training drug. Time-course effects of a 
drug may be assessed by conducting multiple tests in extinction (i.e., one test is conducted 60 
min post-administration, and a second test is conducted 90 min post-administration). 
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Statement of the Problem 
 Kava-kava is a widely available and used herbal medicine that is not regulated in many 
countries, including the United States. There are many questions concerning kava’s stimulus 
properties, potential for therapeutic use, and potential for abuse. Although there is evidence that 
kava may possess some anxiolytic properties, the extent to which it may serve as an alternative 
to pharmaceutical anxiolytics and the supplement’s mechanism of action are unknown. To date, 
there is no research examining whether kava shares discriminative-stimulus properties with a 
standard pharmaceutical anxiolytic such as CDP. Shared discriminative-stimulus properties 
would suggest that kava may share other properties of pharmaceutical anxiolytics such as the 
mechanism of action or abuse potential. The current study compared different doses of kava in 
two groups of rats trained to discriminate either a high or low training dose of CDP.  A positive 
control (multiple doses of CDP) and negative control (the stimulant d-amphetamine) was also 
incorporated in testing. Two generalization tests were conducted within each test session (Test 




 Sixteen experimentally naïve male Sprague-Dawley rats were used as subjects, and were 
approximately two months of age at the start of the experiment. Rats were housed individually 
with free access to water in their home cages. Temperature and humidity were maintained at 
constant levels and there was a reversed 12-hour light-dark cycle in effect. All sessions were 
conducted during the dark phase of the light-dark cycle. The subjects were fed approximately 15 
8 
g of food one half hour following each experimental session. This schedule resulted in 
approximately 22 hours of food deprivation prior to the start of each session. 
Apparatus 
 Experimental sessions were conducted in eight standard operant-conditioning chambers 
for rats, each enclosed in a melamine sound-attenuating cubicle (Med Associates, VT). Each 
chamber contained a working area of 30.5 cm by 24.5 cm by 21.0 cm, a grid floor, and a 45-mg 
pellet dispenser with a pellet receptacle centered between two retractable response levers. The 
levers were 11.5 cm apart from each other and required at least a force 0.25 N for a response to 
be recorded. The levers were 4.8 cm wide, protruded 1.9 cm into the chamber, and were elevated 
8 cm from the grid floor. Two 28-V stimulus lights that were 2.5 cm in diameter were 
approximately 7 cm above each lever. Each chamber contained a 28-V houselight on the wall 
opposite to wall containing the operandum. A ventilation fan circulated air and served to mask 
extraneous noise. Equipment was interfaced to a computer and experimental sessions and data 
collection was programmed and conducted with MedPC-IV (Med Associates, VT). 
Procedure 
Initial Training. Training sessions were conducted five days a week (Monday through 
Friday) at approximately the same time each day. The subjects were trained to lever press using a 
free-operant acquisition procedure (cf: van Haaren, 1992; Anderson & van Haaren, 1999). Each 
rat was placed in a darkened experimental chamber and the ventilation fan was turned on. Ten 
min later, the houselight and stimulus lights above both levers were illuminated. Food was 
delivered according to a conjoint FR 1 variable-time (VT) 60-s schedule. Values for the VT were 
obtained using a Fleshler-Hoffman sequence generator (Fleshler-Hoffman, 1962). Rats received 
one food pellet either after a lever press or after an average of 60 s has elapsed. If any subjects 
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failed to acquire the response following the lever-press training procedure, the lever-press was 
shaped through reinforcement of successive approximations. When subjects were obtaining most 
food pellets via the lever press, subjects then completed an FR 1 schedule that alternated between 
the left and right levers after the delivery of five food pellets on each lever for 40 food pellets 
total. The ratio was increased gradually over consecutive sessions until an FR 10 was reached. 
The next phase of lever press acquisition training consisted of a VI 15-s schedule. After 
responding reliably on the VI 15-s schedule, subjects were then exposed to a VI 30-s schedule. 
The subjects entered the next phase of the experiment after responding reliably on a VI 30-s 
schedule.  
Discrimination training. The subjects were divided into two groups of eight rats. Sessions 
were conducted five, and then seven days a week. Initially, training began with a relatively low 
training dose of CDP (3.0 mg/kg) for one group. The other group was exposed to a higher 
training dose of CDP (17.0 mg/kg). The training doses were subsequently adjusted in order to 
facilitate discrimination (i.e., the low training dose was increased to CDP 5.6 mg/kg), or to 
decrease response suppression (i.e., the high training dose was decreased to CDP 13.0 mg/kg). 
One of the subjects in the high-dose training group was changed to the lower training dose after 
failing to respond following drug administration. The drug (D) or saline vehicle (V) was 
administered via i.p. injection prior to each daily session in the following order for each two-
week period (Monday-Friday): VDVDD DVDVV. Following the injection, the subject was 
placed immediately in the darkened experimental chamber and the ventilation fan was turned on. 
After a period of 15 min, the houselight and both lever lights were illuminated, and both levers 
were extended into the chamber. Food pellet presentation followed responses on the vehicle- or 
drug-appropriate lever according to a tandem VI 30-s FR 10 (TAND (VI 30-s, FR 10)) schedule 
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of reinforcement. For one half of each group, fulfilling the required responses on the left lever 
resulted in food pellet delivery following injection of saline, and responses on the right lever 
resulted in food pellet delivery following injection of CDP. For the other half of each group, the 
levers were counterbalanced such that reinforced responses were on the left lever following CDP 
injection and the right lever following saline injection. Responses on the other lever were 
counted but had no other scheduled consequences (extinction; incorrect lever). Sessions were 
terminated following the presentation of 40 food pellets or 30 min, whichever occurred first. 
After 150 sessions, only one subject had met the original training criteria. Therefore, the dosing 
schedule was slightly modified to constitute a 24-day period (seven days a week): 
VDVDDDVDVDVV DVDVVVDVDVDD. In addition, the VI component of the training 
schedule was removed, and for the rest of the experiment an FR 10 schedule of reinforcement 
was in effect.  
Generalization testing. Generalization testing began after the subjects emitted at least 
80% correct lever presses before the delivery of the first food pellet for five consecutive sessions. 
Rats that did not successfully complete discrimination training were not included in the testing 
phase (i.e., three rats in the low-dose group). Generalization tests were conducted on Tuesdays 
and Fridays, once following a vehicle injection session and once following a drug injection 
session. Each dose of CDP, kava, and d-amphetamine was tested at least twice. The subjects 
were injected (i.p.) and immediately placed in the darkened experimental chamber. After 15 min, 
Test One began. Both levers were extended into the chamber and the houselight and both lever 
lights were illuminated for five min or until completion of the response requirement for FR 10. 
After completing the required responses, instead of delivery of a food pellet, both levers were 
retracted, and the houselight and stimulus lights were darkened until the beginning of Test Two. 
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During the interval between tests, all lights remained extinguished and the levers remained 
retracted from the chamber. If the response requirement was not met within five min of the onset 
of the test, the experimental chamber was darkened and the levers were retracted until Test Two 
began. Thirty min following drug injection, a second generalization test commenced. This test 
was identical to the first and the session was terminated upon its completion. Some 
generalization tests were conducted using an i.p. route of administration for chlordiazepoxide, 
saline, kava extract, and kava vehicle (see Drugs for vehicle composition).  
After several generalization tests following i.p. administration of kava, it was evident that 
kava was not generalizing to the training stimuli, so these data are not presented. In order to rule 
out drug absorption issues due to poor solubility of the compound, a change was made. All drugs 
were administered orally via gastric gavage (p.o.) on test days. Subjects were administered test 
drugs 60 min prior to the start of Test One and placed back into their home cage. Forty-five min 
following drug administration, subjects were placed into the operant-conditioning chamber and 
the ventilation fan was turned on. Fifteen min later, Test One began. Test Two began 90 min 
after drug administration. Contingencies during each test were the same as described above. 
Generalization tests were conducted for CDP (1.0-13.0 mg/kg), d-amphetamine (0.3-3.0 mg/kg), 
saline, kava vehicle, and kava extract (300-560 mg/kg). Most subjects received at least two 
determinations of each dose. However, due to time constraints, some subjects experienced doses 
of kava or d-amphetamine only once. In some instances, drug doses (e.g., kava 560 mg/kg, d-
amphetamine 3.0 mg/kg) suppressed responding almost completely. The data from these 
determinations are excluded from data analyses.  
Drugs. Chlordiazepoxide hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in 
0.9% saline vehicle and administered 15 min prior to training (i.p.) and 60 min prior to testing 
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(p.o.). Kava extract was generously supplied by the National Center for Natural Products 
Research at the University of Mississippi (Oxford, MS). The extract was dissolved in the kava 
vehicle (91% distilled water, 4% ethanol, 4% Tween 80, and 1% dimethyl sulfoxide) and 
administered 60 min prior to testing (p.o.). Kavalactones comprised 84% of the kava extract. The 
kavalactone content was comprised of 49% kavain, 18.6% dihydrokavain, 9.8% methysticin, 
8.4% dihydromethysticin, 5.8% yangonin, and 4.8% desmethoxyangonin. d-Amphetamine 
(Sigma-Aldrich Company, St. Louis, MO) was dissolved in 0.9% saline and administered 60 min 
prior to testing (p.o.).  
Data analysis. The percentage of correct (injection-appropriate) lever presses in training 
was determined by dividing the number of responses made on the injection-appropriate lever by 
the number of total responses made on both levers preceding the delivery of the first food pellet. 
Response rate (responses per min) on the injection-appropriate lever in training was determined 
by dividing the total number of lever presses on the injection-appropriate lever by the duration 
(min) of each session. Training data were represented graphically in which the percent choice of 
injection-appropriate lever was plotted as a function of injection type (drug or saline).   
Calculations were the same for the generalization tests, except data collection ended 
when the required responses were made or when the session timed out. Only data following oral 
administration of the test drugs are presented. In testing, only percentage of total responses and 
response rate on the CDP-appropriate were calculated and plotted. Test data were not included if 
subjects failed to fulfill the schedule requirement (i.e., ten responses were not emitted on a single 
lever). In the case where partial substitution of a test compound was found, the percentage of 
total responses emitted on the CDP-appropriate lever was tested for significance with a 3-way 
repeated measures ANOVA. Occasionally, subjects did not receive a test dose or failed to 
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respond following a test dose. In these cases, data were interpolated from the group mean for that 
dose. In the case that main effects (training group, test time, drug dose) were found, t-tests were 
conducted as post-hoc analyses. The median effective dose (ED50) for each drug was calculated 
by log-linear interpolation of the descending portion of the dose-effect curve. For all statistical 
tests, p < 0.05 was considered to be significant. The percentage of responses emitted greater than 
or equal to 80% on the CDP lever was considered to be full substitution, 21-79% partial 
substitution, and less than or equal to 20% no substitution.  
Results 
Discrimination Training. The CDP discrimination required an average of 40 training 
sessions on FR 10 for the low-dose group (range 25-62 sessions) and an average of 32 sessions 
(range 23-49 sessions) for the high-dose group. For the last ten sessions of the training phase, the 
mean percent correct lever responding was 93.7% (range 86.6-100%) for the low-dose training 
group and 95.9% (range 88.6-100%) for the high-dose training group. The mean response rate on 
the stimulus-appropriate lever was 64.5 rsp/min (range 56.6-82.0 rsp/min) and 62.3 rsp/min 
(range 52.9-73.4 rsp/min) for the low-dose and high-dose group, respectively. Subsequent t-tests 
revealed no significant differences between groups for mean percentage of total responses or 
response rate on the stimulus-appropriate lever.  
Generalization of CDP. In general, full substitution of CDP was found at doses 
equivalent to and above that of the training dose for both groups in Test One (Figure 1). In both 
groups, doses smaller than the training dose only partially substituted for the training dose. The 
percentage of total responses emitted on the CDP-appropriate lever was functionally related to 
the dose of CDP administered. The lower ED50 value in the low-dose group (especially in Test 
One) suggests greater sensitivity to the discriminative-stimulus effects of CDP administration. 
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During Test One, the ED50s for the low-dose and high-dose groups were CDP 2.9 mg/kg and 
CDP 5.9 mg/kg, respectively. However, subsequent t-tests did not reveal any significant 
differences in ED50 values between groups. Individual data during Test One following 
administration (p.o.) of CDP are presented in Table 1.  
On average, full substitution of the training dose was found in the high-dose group, but 
only partial substitution was found in the low-dose group during Test Two (Figure 1). Three of 
the rats in the low- training group and only one in the high-dose group emitted at least 80% of 
total responses on the CDP lever during Test Two following administration of the training dose. 
In both groups, the average percentage of total responses emitted on the CDP-appropriate lever 
was functionally related to CDP dose, such that the average percentage increased as the dose size 
increased. The ED50s for the low-dose and high-dose groups were CDP 3.5 mg/kg and CDP 3.3 
mg/kg, respectively. Subsequent t-tests did not reveal any significant differences in ED50 values 
between subjects. Individual data during Test Two following CDP administration are presented 
in Table 2. 
Response rates on the CDP-appropriate lever were also calculated during both tests. For 
both groups, the mean response rate on the CDP-appropriate lever was functionally related to the 
dose of CDP administered (Figure 2) during Test One. The response rate on the CDP-appropriate 
lever systematically increased as the dose of CDP increased. During Test One, the average 
response rate on the CDP-appropriate lever for the low-dose group (52.9 rsp/min) was lower than 
that of the high-dose group (77.2 rsp/min) following administration of the training dose. 





Mean Percent Responding, S.E.M, and Number of Determinations for Each dose (SEM, determinations) on CDP-appropriate Lever 
Following CDP Administration (mg/kg, p.o.) in Individual Subjects During Test One 
 
  Training Test One 
Rat ID Dose CDP 1.0 CDP 3.0 CDP 5.6 CDP 10.0 CDP 13.0 
S60-2 Low (5.6) 71.1 (9.7, 3) 9.1 (0.0, 2) 75.0 (22.1, 4) - - 
S60-4 Low (5.6) 4.5 (4.5, 2) 44.0 (27.4, 2) 87.1 (3.8, 2) 95.5 (4.5, 2) - 
S60-5 Low (5.6) 0.0 (0.0, 2) 96.9 (3.0, 3) 95.5 (4.5, 2) - - 
S60-8 Low (5.6) 16.7 (16.7, 2) 91.7 (8.3, 2) 100.0 (0.0, 2) 100.0 (0.0, 2) - 
S70-5 Low (5.6) 33.3 (33.3, 3) 50.0 (50.0, 2) 100.0 (0.0, 2) 100.0 (0.0, 1) - 
S70-7 Low (5.6) 11.5 (11.5, 2) 66.7 (33.3, 3) 89.3 (6.7, 3) 100.0 (0.0, 1) - 
Group mean 27.3 (9.8) 62.9 (11.8) 88.9 (6.0) 98.5 (1.5) - 
       
S70-3 High (13.0) 33.3 (33.3, 3) 0.0 (0.0, 2) 33.3 (33.3, 3) - 100.0 (100.0, 3) 
S70-4 High (13.0) - 0.0 (0.0, 2) 4.5 (4.5, 2) - 81.4 (9.5, 3) 
S60-7 High (13.0) 0.0 (0.0, 1) 27.3 (24.3, 4) 100.0 (0.0, 2) - 100.0 (0.0, 3) 




Mean Percent Responding, S.E.M, and Number of Determinations for Each dose (SEM, determinations) on CDP-appropriate Lever 
Following CDP Administration (mg/kg, p.o.) in Individual Subjects During Test Two 
  Training Test Two 
Rat ID Dose CDP 1.0 CDP 3.0 CDP 5.6 CDP 10.0 CDP 13.0 
S60-2 Low (5.6) 50.5 (24.8, 3) 26.8 (17.7, 2) 55.0 (26.0, 4) - - 
S60-4 Low (5.6) 0.0 (0.0, 2) 62.5 (19.7, 2) 100.0 (0.0, 2) 37.9 (14.8, 2) - 
S60-5 Low (5.6) 57.0 (33.9, 2) 69.7 (30.3, 3) 100.0 (0.0, 2) - - 
S60-8 Low (5.6) 0.0 (0.0,2) 0.0 (0.0,2) 100.0 (0.0, 2) 68.8 (31.2, 2) - 
S70-5 Low (5.6) 66.7 (33.3, 3) 50.0 (50.0, 2) 100.0 (0.0, 2) 100.0 (0.0, 1) - 
S70-7 Low (5.6) 35.7 (35.7, 2) 64.1 (27.9, 3) 57.1 (29.7, 3) 100.0 (0.0, 1) - 
Group mean 38.4 (11.6) 45.8 (11.6) 67.0 (11.7) 68.9 (14.4) - 
       
S70-3 High (13.0) 0.0 (0.0, 3) 100.0 (0.0, 2) 72.2 (27.8, 3) - 100.0 (0.0, 3) 
S70-4 High (13.0) - 0.0 (0.0, 2) 0.0 (0.0, 2) - 71.3 (24.2, 3) 
S60-7 High (13.0) 9.1 (0.0, 1) 0.0 (0.0, 4) 100.0, (0.0, 2) - 69.7 (30.3, 3) 




Mean Percent Responding, S.E.M, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever 
Following d-Amphetamine Administration (mg/kg, p.o.) in Individual Subjects 
 
  Training Test One Test Two 
Rat ID Dose Saline d-amp 0.3 d-amp 1.0 d-amp 3.0 Saline d-amp 0.3 d-amp 1.0 d-amp 3.0 
S60-2 Low (5.6) 18.0 (3.3, 4) 16.7 (0.0, 1) 9.1 (0.0, 1) - 6.4 (4.0, 4) 0.0 (0.0, 1) 55.6 (0.0, 1) - 
S60-4 Low (5.6) 0.0 (0.0, 5) - 8.3 (8.3, 2) 11.1 (11.1, 2) 31.8 (20.5, 5) - 8.3 (8.3, 2) 0.0 (0.0, 2) 
S60-5 Low (5.6) 2.3 (2.3, 4) 0.0 (0.0, 3) 0.0 (0.0, 3) - 2.3 (2.3, 4) 31.9 (18.1, 3) 30.3 (30.3, 3) - 
S60-8 Low (5.6) 0.0 (0.0, 3) - 0.0 (0.0, 2) 0.0 (0.0, 2) 0.0 (0.0, 3) - 0.0 (0.0, 2) 0.0 (0.0, 2) 
S70-5 Low (5.6) 0.0 (0.0, 2) 0.0 (0.0, 3)  - 50.0 (50.0, 2) 30.3 (30.3, 3) 0.0 (0.0, 2) - 
S70-7 Low (5.6) 0.0 (0.0, 4) 23.8 (23.8, 4) 43.1 (21.6, 3) - 9.4 (9.4, 4) 69.8 (4.6, 4) 55.6 (27.8, 3) - 
Group mean 3.7 (1.6) 16.3 (9.9) 11.9 (6.6) 6.7 (6.7) 13.8 (6.1) 42.4 (11.0) 25.4 (10.5) 0.0 (0.0) 
S70-3 High (13.0) 0.0 (0.0, 3) 0.0 (0.0, 3) 0.0 (0.0, 2) - 0.0 (0.0, 3) 38.9 (30.9, 3) 0.0 (0.0, 2) - 
S70-4 High (13.0) 0.0 (0.0, 4) 0.0 (0.0, 2) 0.0 (0.0, 2) - 12.6 (8.4, 4) 18.8 (9.7, 2) 0.0 (0.0, 2) - 
S60-7 High (13.0) 0.0 (0.0, 4) - 0.0 (0.0, 2) 0.0 (0.0, 2) 0.0 (0.0, 4) - 0.0 (0.0, 2) 0.0 (0.0, 2) 






Mean Percent Responding, SEM, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever 
Following Kava Administration (mg/kg, p.o.) in Individual Subjects 
 
  Training Test One Test Two 
Rat ID Dose kava vehicle kava 300 kava 560 kava vehicle kava 300 kava 560 
S60-2 Low (5.6) 23.1 (0.0, 1) 23.1 (0.0, 1) 33.9 (24.9, 2) 9.1 (0.0, 1) 9.1 (0.0, 1) 54.5 (45.5, 2)
S60-4 Low (5.6) 4.5 (2.5, 2) 0.0 (0.0, 2) 33.3 (28.9, 3) 4.5 (4.5, 2) 19.9 (3.2, 2) 8.6 (4.8, 3) 
S60-5 Low (5.6) 33.3 (33.3, 3) 13.7 (13.7, 3) 95.5 (4.5, 2) 30.3 (30.3, 3) 24.8 (12.6, 3) 4.5 (4.5, 2) 
S60-8 Low (5.6) 10.3 (10.3, 4) 0.0 (0.0, 2) 0.0 (0.0, 2) 0.0 (0.0, 4) 0.0 (0.0, 2) 0.0 (0.0, 2) 
S70-5 Low (5.6) 0.0 (0.0, 1) 0.0 (0.0, 2) 0.0 (0.0, 3) 9.1 (0.0, 1) 8.3 (8.3, 2) 66.7 (33.3, 3)
S70-7 Low (5.6) 0.0 (0.0, 2) 0.0 (0.0, 2) 91.7 (18.3, 2) 0.0 (0.0, 2) 28.2 (5.1, 2) 69.0 (2.4, 2) 
Group mean 15.8 (9.3) 5.4 (3.8) 38.7 (12.0) 7.8 (3.8) 17.7 (7.4) 34.4 (11.4) 
S60-7 High (13.0) 0.0 (0.0, 2) 0.0 (0.0, 3) 0.0 (0.0, 3) 0.0 (0.0, 2) 5.6 (5.6, 3) 9.5 (9.5, 3) 
S70-3 High (13.0) 0.0 (0.0, 1) 4.5 (4.5, 3) 30.3 (30.3, 1) 0.0 (0.0, 1) 33.3 (33.3, 3) 0.0 (0.0, 1) 
S70-4 High (13.0) 0.0 (0.0, 1) 11.1 (11.1, 2) 42.9 (29.7, 3) 0.0 (0.0, 1) 0.0 (0.0, 2) 30.3 (30.3, 3)




Mean Responses per Minute, SEM, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever 
Following CDP Administration (mg/kg, p.o.) in Individual Subjects During Test One 
  Training Test One 
Rat ID Dose CDP 1.0 CDP 3.0 CDP 5.6 CDP 10.0 CDP 13.0 
S60-2 Low (5.6) 34.4 (10.2, 3) 4.3 (0.3, 2) 48.4 (15.4, 4) - - 
S60-4 Low (5.6) 2.8 (2.8, 2) 18.7 (8.7, 2) 66.0 (19.8, 2) 76.2 (9.5, 2) - 
S60-5 Low (5.6) 0.0 (0.0,2) 44.8 (8.3, 3) 38.1 (8.1, 2) - - 
S60-8 Low (5.6) 11.6 (11.6, 2) 59.7 (40.3, 2) 75 (0.0, 2) 85 (35.0, 2) - 
S70-5 Low (5.6) 13.3 (13.3, 3) 16.7 (16.7, 2) 70.2 (15.6, 2) 100.0 (0.0, 1) - 
S70-7 Low (5.6) 3.8 (3.8, 2) 25.9 (13.6, 3) 33.7 (8.2, 3) 50.0 (0.0, 1) - 
Group mean 12.8 (4.7) 29.4 (7.4) 52.9 (6.2) 78.8 (11.5) - 
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S70-3 High (13.0) 37.5 (37.5, 3) 0.0 (0.0,2) 20 (39.2, 3) - 19.2 (3.4, 3) 
S70-4 High (13.0) - 0.0 (0.0,2) 5.0 (5.0, 2) - 75.8 (34.7, 3) 
S60-7 High (13.0) 0.0 (0.0, 1) 28.0 (24.2, 4) 85.7 (0.0, 2) - 106.7 (6.7, 3) 




Mean Responses per Minute, SEM, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever 
Following CDP Administration (mg/kg, p.o.) in Individual Subjects During Test One 
  Training Test Two 
Rat ID Dose CDP 1.0 CDP 3.0 CDP 5.6 CDP 10.0 CDP 13.0 
S60-2 Low (5.6) 16.9 (10.4, 3) 11.4 (7.9, 2) 24.0 (12.0, 4) - - 
S60-4 Low (5.6) 0.0 (0.0,2) 16.5 (12.1, 2) 44.9 (9.6, 2) 5.9 (0.3, 2) - 
S60-5 Low (5.6) 17.7 (13.9, 2) 16.5 (7.3, 3) 34.6 (3.0, 2) - - 
S60-8 Low (5.6) 0.0 (0.0, 2) 0.0 (0.0, 2) 0.0 (0.0, 2) 31.0 (25.3, 2) - 
S70-5 Low (5.6) 29.3 (5.5, 3) 13.1 (13.1, 2) 42.6 (7.4, 2) 60.0 (0.0, 1) - 
S70-7 Low (5.6) 15.0 (15.0, 2) 18.5 (10.2, 3) 14.3 (8.3, 3) 18.2 (0.0, 1) - 
Group mean 14.6 (4.2) 12.4 (3.3) 25.5 (5.2) 25.3 (10.6) - 
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S70-3 High (13.0) 0.0 (0.0,3) 30.0 (0.0, 2) 26.1 (12.9, 3) - 40.5 (3.2, 3) 
S70-4 High (13.0) - 0.0 (0.0,2) 0.0 (0.0, 2) - 25.6 (4.0, 3) 
S60-7 High (13.0) 5.5 (0.0, 1) 21.4 (21.4, 4) 70.2 (15.6, 2) - 28.8 (24.1, 3) 




Mean Responses per Minute, SEM, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever 
Following d-amphetamine Administration (mg/kg, p.o.) in Individual Subjects 
  Training Test One Test Two 
Rat ID Dose Saline d-amp 0.3 d-amp 1.0 d-amp 3.0 Saline d-amp 0.3 d-amp 1.0 d-amp 3.0 
S60-2 Low (5.6) 6.8 (1.4, 4) 1.8 (0.0, 1) 4.3 (0.0, 1) - 0.1 (0.7, 4) 0.0 (0.0, 1) 25.0 - 
S60-4 Low (5.6) 0.0 (0.0, 5) - 2.9 (2.9, 2) 1.0 (1.0, 2) 10.2 (7.0, 5) - 2.1 (2.1) 0.0 (0.0, 2) 
S60-5 Low (5.6) 0.6 (0.6, 4) 0.0 (0.0, 3) 0.0 (0.0, 3) - 0.4 (0.4, 4) 8.3 (5.5, 3) 3.0 (3.0) - 
S60-8 Low (5.6) 0.0 (0.0, 3) - 0.0 (0.0, 2) 0.0 (0.0, 2) 0.0 (0.0, 3) - 0.0 (0.0, 2) 0.0 (0.0, 2) 
S70-5 Low (5.6) 0.0 (0.0, 2) 0.0 (0.0, 3) 0.0 (0.0, 2) - 7.2 (7.2, 2) 8.7 (8.7, 3) 0.0 (0.0, 2) - 
S70-7 Low (5.6) 0.0 (0.0, 4) 14.4 (8.7, 4) 8.8 (6.8, 3) - 1.6 (1.6, 4) 21.0 (3.8, 4) 17.9 (9.0) - 
Group mean 1.3 (0.6) 5.4 (3.6) 2.8 (1.7) 0.6 (0.6) 3.5 (1.8) 12.3 (3.5) 7.1 (3.1) 0.0 (0.0) 
S70-3 High (13.0) 0.0 (0.0, 3) 0.0 (0.0, 3) 0.0 (0.0, 2) - 0.0 (0.0, 3) 10.4 (9.1, 3) 0.0 (0.0, 2) - 
S70-4 High (13.0) 0.0 (0.0, 4) 0.0 (0.0, 2) 0.0 (0.0, 2) - 0.0 (0.0, 4) 11.8 (4.3), 2 0.0 (0.0, 2) - 
S60-7 High (13.0) 0.0 (0.0, 4) - 0.0 (0.0, 2) 0.0 (0.0, 2) 0.0 (0.0, 4) - 0.0 (0.0, 2) 0.0 (0.0, 2) 







Mean Responses per Minute, SEM, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever 
Following Kava Administration (mg/kg, p.o.) in Individual Subjects 
  Training Test One Test Two 
Rat ID Dose kava vehicle kava 300 kava 560 kava vehicle kava 300 kava 560 
S60-2 Low (5.6) 9.0 (0.0, 1) 6.0 (0.0, 1) 13.7 (9.4, 2) 2.1 (0.0, 1) 2.1 (0.0, 1) 30.7 (29.4, 2) 
S60-4 Low (5.6) 2.5 (2.5, 2) 0.0 (0.0, 2) 16.4 (14.9, 3) 0.4 (0.4, 2) 1.3 (0.7, 2) 0.9 (0.6, 3) 
S60-5 Low (5.6) 13.7 (13.7, 3) 1.6 (1.6, 3) 23.9 (7.7, 2) 11.4 (1.7, 3) 4.8 (4.8, 3) 0.7 (0.7, 2) 
S60-8 Low (5.6) 2.9 (2.9, 4) 0.0 (0.0, 2) 0.0 (0.0, 2) 0.0 (0.0, 4) 0.0 (0.0, 2) 0.0 (0.0, 2) 
S70-5 Low (5.6) 0.0 (0.0, 1) 0.0 (0.0, 2) 0.0 (0.0, 2) 1.3 (0.0, 1) 2.7 (2.7, 2) 23.9 (12.2, 3) 
S70-7 Low (5.6) 0.0 (0.0, 2) 0.0 (0.0, 2) 33.0 (9.9, 3) 0.0 (0.0, 2) 7.8 (2.5, 2) 9.9 (0.8, 2) 
Group mean 4.4 (2.4) 0.9 (0.6) 13.6 (4.5) 2.2 (1.3) 3.3 (1.4) 11.2 (5.1) 
S60-7 High (13.0) 0.0 (0.0, 2) 0.0 (0.0, 3) 0.0 (0.0, 3) 0.0 (0.0, 2) 5.0 (5.0, 3) 4.0 (4.0, 3) 
S70-3 High (13.0) 0.0 (0.0, 1) 0.0 (0.0, 2) 0.0 (0.0, 3) 0.0 (0.0, 1) 6.9 (6.9, 2) 0.0 (0.0, 3) 
S70-4 High (13.0) 0.0 (0.0, 1) 10.0 (10.0, 3) 30.0 (17.3, 2) 0.0 (0.0, 1) 0.0 (0.0, 3) 22.2 (22.2, 2) 
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Drug Dose (mg/kg)  
 Figure 1. Mean percent and SEM of total responses emitted on the CDP-appropriate lever for each of the test doses of CDP, d-
Amphetamine, kava, kava vehicle, and saline for the low-dose training group (left panels) and high-dose training group (right 
panels) as a function of test dose. The top graphs reflect responding 60 min following administration of the test drug (Test One), 
and the bottom graphs reflect responding 90 min post-administration (Test Two).  
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Drug Dose (mg/kg) 
Figure 2. Mean response rate and SEM on the CDP-appropriate lever for each of the test doses of CDP, d-amphetamine, kava, 
kava vehicle, and saline for the low dose training group (left panels) and high-dose training group (right panels) as a function of 
test dose. The top graphs reflect responding 60 min following administration of the test drug (Test One), and the bottom graphs 
reflect responding 90 min post-administration (Test Two). 
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During Test Two, the average response rate on the CDP-appropriate lever was lower than that 
found during Test One for both groups. As found in Test One, the average response rate for the 
low-dose group (25.5 rsp/min) was lower than that found for the high-dose group (31.0 rsp/min). 
In general, the response rate on the CDP-appropriate lever systematically decreased as a function 
of dose for both groups. Group means and individual data for response rate on CDP-appropriate 
lever in Test Two are presented in Figure 2 and Table 6, respectively. 
 Generalization of saline vehicle. The average percentage of total responses and response 
rate on the CDP-appropriate lever during both tests following saline administration was also 
calculated. Saline served as the vehicle for both CDP and negative control d-amphetamine. For 
both groups, no substitution following saline administration was found in either test. Group 
means and individual data for percent responding on the CDP-appropriate lever during Test One 
are presented in Figure 1 and Table 2, respectively. Test Two group means (Figure 2) and 
individual data (Table 6) for response rates on the CDP-appropriate lever following saline 
administration are also presented. 
Generalization of d-amphetamine (negative control). In general, evidence of substitution 
of d-amphetamine was not found during Test One. However, partial substitution was found in 
Test Two. The 3-way repeated measures ANOVA revealed a main effect of percentage of total 
responses emitted on the CDP-appropriate lever for d-amphetamine of test time, F(1, 7) = 39.5, p 
< 0.01, and group, F(1, 7) = 20.6, p = 0.05. No main effect was found for dose, F(2, 14) = 2.5, p 
= 0.11. Because only three of nine subjects fulfilled the response requirement following 
administration of d-amphetamine 3.0 mg/kg, these data were not included in the analyses.  
Administration of negative control d-amphetamine (0.3-3.0 mg/kg) did not occasion 
responding indicative of substitution during Test One in either group of rats (Figure 1). The low-
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dose group (6.7-16.3%) emitted a higher average percentage of responses more than the high-
dose group (0.0-0.0%) on the CDP-appropriate lever following administration of d-
amphetamine. With the exception of one subject (S70-7), partial substitution of d-amphetamine 
was not found in individual subjects (Table 3). The average response rate on the CDP-
appropriate lever in Test One was found to systematically increase as the dose of d-amphetamine 
decreased in the low-dose group (Figure 2). The low-dose group (M = 17.6, SEM = 3.3) had a 
higher average percentage of total responses on the CDP-appropriate lever following d-
amphetamine administration than the high-dose group (M = 5.6, SEM = 2.8). Response rates on 
the CDP-appropriate lever during Test One for individual subjects are presented in Table 7. 
During Test Two, administration of the lower doses of d-amphetamine resulted in 
responding on the CDP-appropriate lever indicative of partial substitution in both groups (Figure 
1). As was found in Test One, the average percentage of responses and response rate on the 
CDP-appropriate lever following d-amphetamine administration was slightly higher in the low-
dose group (0.0-42.4%) than the high-dose group (0.0-30.9%). On average, the percentage of 
total responses emitted on the CDP-appropriate lever following d-amphetamine administration 
was significantly more during Test Two (M = 21.0, SEM = 4.2) than during Test One (M = 6.1, 
SEM = 2.0). Individual data for average percentage of total responses on the CDP-appropriate 
lever are presented in Table 1. The average percentage of total responses (Figure 1) and response 
rate (Figure 2) on the CDP-appropriate lever systematically increased as the dose of d-
amphetamine decreased. Response rates on the CDP-appropriate for individual subjects (Table 7) 
during Test Two are presented. 
Generalization of kava. In general, partial substitution of kava was found in both groups 
at Test One, but only the low-dose group during Test Two. The percent of total responses 
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emitted and response rate on the CDP-appropriate lever was functionally related to dose with an 
average of 38.7% maximum substitution at any dose. The 3-way repeated measures ANOVA 
revealed a significant main effect of kava dose, F(2, 14) = 6.1, p = .01 with average percentage 
of total responses on the CDP-appropriate lever. No main effects were found for test time, F(1, 
7) = .03, p = .86 or group, F(1, 7) = 1.76, p = .23. 
Partial substitution of kava was found for kava 560 mg/kg in both groups during Test 
One (Figure 1). Subjects emitted a significantly higher average percentage of total responses on 
the CDP-appropriate lever following administration of kava 560 mg/kg (M = 10.1, SEM = 2.6) 
than kava 300 mg/kg (M = 31.7, SEM = 7.6). A subsequent t-test revealed a significant 
difference of percentage of total responses on the CDP-appropriate lever between kava vehicle 
and kava 560 mg/kg (p < .05). The average percent responding on the CDP-appropriate lever 
was slightly higher in the low-dose group (maximum 38.7 %) than the high-dose group 
(maximum 31.4%). However, two rats in the low-dose group and one rat in the high-dose group 
did not respond on the CDP-appropriate lever following administration of kava (Table 4). Partial 
substitution was not found following administration of kava 300 mg/kg, except for one rat in the 
low-dose group (S60-2). Following administration of kava, the response rate on the CDP-
appropriate lever was functionally related to dose. No substitution was found in either group 
during Test One for kava vehicle. Group data for response rates on the CDP-appropriate lever are 
presented in Figure 2. Response rates on the CDP-appropriate lever individual data are presented 
in Table 8. 
  Partial substitution of kava was found during Test Two for kava 560 mg/kg in the low-
dose group only (Figure 1). In this group, the average percentage of total responses and response 
rate on the CDP-appropriate lever were slightly lower in Test Two than Test One following 
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administration of kava 560 mg/kg. Following administration of kava, the response rate on the 
CDP-appropriate lever was functionally related to dose in both groups. On average, 
administration of kava 300 mg/kg did not result in partial substitution for either group. However, 
two subjects in the low-dose group and one subject in the high-dose group did emit at least 20% 
of the total responses on the CDP-appropriate lever. No substitution was observed following 
administration of kava vehicle in either group during Test Two (Figure 1). Individual data for 
percent responding (Table 4) and response rate (Table 8) on the CDP-appropriate lever during 
Test Two following kava administration are presented. 
Discussion 
Dose-dependent substitution of CDP was found in both the low and high-dose training 
groups. Although the low-dose group appeared to be more sensitive to the effects of CDP 
because of the lower ED50 values, no significant differences were found between groups. The 
negative control d-amphetamine did not substitute for CDP in either group during Test One. 
However, during Test Two, marginal substitution was found in both groups at the lower doses of 
d-amphetamine. Kava 560 mg/kg was found to occasion partial substitution in both groups 
during Test One and only the low-dose group during Test Two. 
Administration of kava 560 mg/kg resulted in partial substitution for the training dose of 
CDP in both groups 60 min post-administration (Test One). Ninety min post-administration (Test 
Two), partial substitution was observed in the low-dose group only. However, the extent to 
which kava 560 mg/kg generalized to the training dose was modest (i.e., 31.4%–38.7%). For 
some rats, full substitution was observed following administration of kava 560 mg/kg. Individual 
differences in sensitivity to methods and drugs used in the present experiment may have 
contributed to the variability in substitution observed. Several procedural variables may have 
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influenced the present results. One potential variable that may have influenced the findings is 
that the training doses of CDP may have engendered poor stimulus control for other potential 
GABAA agonists like kava. Perhaps utilizing a shorter-acting benzodiazepine (e.g., midazolam) 
for discrimination training may enhance stimulus control. It is possible that administration of 
kava results in effects that are more sedative than anxiolytic (see discussion below). Therefore, it 
may be worthwhile to investigate the discriminative-stimulus effects of kava in rats trained to 
discriminate a short-acting barbiturate from saline.  
Perhaps characteristics of the particular preparation of kava used in this study may have 
influenced the present results. Kava dose-dependently increased the average percentage of total 
responding on the CDP-appropriate lever to a range considered as partial substitution. At higher 
doses, kava may fully substitute for CDP. It is possible that administration of kava had effects on 
motivation (i.e., kava had anorexic effects). However, this is unlikely because subjects consumed 
all of the daily food that was provided 30 min following completion of the session. Previous 
research had indicated that particular kavalactones, particularly dihydrokavain, might mediate 
effects similar to benzodiazepines in behavioral tests (e.g., Feltenstein et al, 2003). Perhaps the 
preparation of kava extract used in this study did not have a high enough content of a particular 
kavalactone to occasion full substitution. The samples used by Feltenstein et al. that resulted in 
anxiolytic effects contained 15.0-67.5% dihydrokavain, while the sample used in this experiment 
contained 18.6% dihydrokavain. Future work may test effects of different samples of kava 
extract containing higher concentrations of different kavalactones. Another possibility would be 
to examine effects of dihydrokavain or other kavalactones administered alone, instead of within 
the kava extract. However, there is reason to believe that the extract was behaviorally active, as 
subjects were visibly sedated and sometimes failed to respond following administration of kava 
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560 mg/kg. Four subjects in the high-dose group died or had to be euthanized due to 
gastrointestinal complications that may or may not have been related to kava administration. In 
2002, the FDA issued a warning pertaining to the potential harmful effects of kava. It is possible 
that the doses of kava used were having harmful effects on the subjects. Because of the potential 
toxic effects of this drug, future research investigating kava’s use as an herbal medicine is 
warranted.  
Another variable that may have influenced the present results was the change in training 
doses in both groups. In order to obtain a reliable discrimination between CDP and saline, a few 
modifications were made to the procedure. Administration of CDP 3.0 mg/kg failed to generate 
discriminated responding in the low-dose group. When the training dose was increased to 5.6 
mg/kg and the response requirement was reduced to FR 10 (see discussion below), most subjects 
acquired the discrimination. In the high-dose group, CDP 17.0 mg/kg suppressed responding 
almost entirely. When the training dose was decreased to CDP 13.0 mg/kg, all subjects acquired 
the discrimination and the average response rate was only slightly lower than that of the low-
dose group.  
In addition to modifying the training doses of CDP, the reinforcement schedule had to be 
modified during training in order to facilitate discrimination. The VI component of the tandem 
VI 30-s FR 10 was removed, and only an FR 10 schedule of reinforcement was in effect. As a 
result, this resulted in data that were more quantal in nature, due to the all-or-none responding 
that often occasion FR schedules of reinforcement (e.g., Stolerman, 1993). 
Another variable that may have influenced the results of the present experiment is the 
altered route of administration during testing. In order to test substitution of kava, drugs had to 
be administered orally on test days. Although CDP was still administered i.p. on training days, 
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using the p.o. route of administration on testing days did not seem to affect substitution of CDP. 
The training doses of CDP administered orally engendered full substitution in both training-dose 
groups. The subjective effects of the drugs appeared to be the same, regardless of route of 
administration.  
Interestingly, during Test Two the negative control d-amphetamine 0.3 mg/kg (in both 
groups) and d-amphetamine 1.0 mg/kg (in the low-dose group) partially substituted for CDP. 
However, the extent of the substitution was only marginal, and may have been due to effects of 
extinction in Test One (i.e., no food received after fulfilling the response requirement during Test 
One might occasion responding on opposite lever during Test Two). It may be useful to examine 
sessions in which effects of different time courses are examined individually (e.g., Anderson and 
van Haaren, 1999). These authors investigated the hypothesis that a drug’s time-course effects 
may be evaluated within subjects and within a single session. Two generalization tests were 
given following cocaine administration, one at 10 min and one at 30 min. However, the authors 
found the effects of exposure to extinction in Test One on responding during Test Two to be 
negligible. There were no differences in generalization gradients that were obtained 30 min after 
cocaine administration, regardless of whether another gradient was obtained after a 
generalization test was conducted 10 min post-administration. This may not have been the case 
in the present study.  
In conclusion, in the present study it was found that kava 560 mg/kg partially substituted 
for the training stimuli in both the high- and low-dose training groups 60 min (both groups) and 
90 min (low-dose group only) post-administration. At 60 min post-administration, kava 560 
mg/kg shared some discriminative-stimulus effects with the training stimuli in both groups. It 
appears as though in the high-dose group, the discriminative-stimulus effects of kava 560 mg/kg 
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were diminishing 90 min post-administration. However, kava 560 mg/kg still partially 
generalized to the training stimulus in the low-dose group 90 min after administration. At 
present, it is unclear why kava failed to fully substitute for the training doses of CDP. Although 
it is possible that administration of kava may not fully substitute for benzodiazepines, further 
research is warranted to rule out other variables that may have influenced the present results. 
Future research may incorporate a different benzodiazepine as a training drug to perhaps 
engender stronger stimulus control. Another possibility that kava failed to fully substitute may be 
due to the particular preparation of kava used in this study, or the chemical structure of kava 
extract itself. In the case that kava acts more as a sedative than anxiolytic, it may generalize to a 
different drug class (e.g., barbiturate). Future research should also examine the possibility that 
extinction during Test One may have resulted in responding on the opposite lever during Test 
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